TiGenix showcases positive 24 week results of its Cx601 Phase III trial at ECCO

21 March 2016

Belgian biopharma firm TiGenix NV (Euronext Brussels: TIG) has presented 24 week results from the Phase III ADMIRE-CD pivotal trial of Cx601 for complex perianal fistulas in Crohn's disease patients, in a plenary session at the 11th Annual Congress of the European Crohn's and Colitis Organization (ECCO) in Amsterdam, The Netherlands.

ADMIRE-CD is a randomized, double-blind, placebo-controlled, Phase III study, designed to investigate the efficacy and safety of a single injection of Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients. Cx601 is a suspension of allogeneic, expanded, adipose-derived stem cells (eASC) for intralesional injection.

MAA already filed in Europe

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK